Related references
Note: Only part of the references are listed.Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000-2017
Ahmed Babiker et al.
CLINICAL INFECTIOUS DISEASES (2021)
Emergence and Expansion of a Carbapenem-Resistant Pseudomonas aeruginosa Clone Are Associated with Plasmid-Borne blaKPC-2 and Virulence-Related Genes
Yanyan Hu et al.
MSYSTEMS (2021)
Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia
Hakeam A. Hakeam et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)
Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates
Maria M. Montero et al.
MICROBIOLOGY SPECTRUM (2021)
Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options
Stamatis Karakonstantis et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Treatment options forK. pneumoniae,P. aeruginosaandA. baumanniico-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems
Stamatis Karakonstantis et al.
INFECTION (2020)
Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales
Antonio Vena et al.
ANTIBIOTICS-BASEL (2020)
Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations
Jason M. Pogue et al.
CLINICAL INFECTIOUS DISEASES (2019)
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K-pneumoniae
Mario Tumbarello et al.
CLINICAL INFECTIOUS DISEASES (2019)
Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
Sarah C. J. Jorgensen et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Risk Factors for Carbapenem-Resistant Pseudomonas aeruginosa, Zhejiang Province, China
Yan-Yan Hu et al.
EMERGING INFECTIOUS DISEASES (2019)
A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology
J. Michael Miller et al.
CLINICAL INFECTIOUS DISEASES (2018)
Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections
Matt Shirley
DRUGS (2018)
Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae
Adrian Sousa et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa
Olga Rodriguez-Nunez et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2018)
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
David van Duin et al.
CLINICAL INFECTIOUS DISEASES (2018)
Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa
Adnan Alatoom et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2017)
2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea
Andi L. Shane et al.
CLINICAL INFECTIOUS DISEASES (2017)
2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis
Allan R. Tunkel et al.
CLINICAL INFECTIOUS DISEASES (2017)
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
David van Duin et al.
CLINICAL INFECTIOUS DISEASES (2016)
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
Mervyn Singer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections
Marco Falcone et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Acute kidney injury in patients using amikacin in an era of carbapenem-resistant bacteria
Felipe Francisco Tuon et al.
INFECTIOUS DISEASES (2016)
In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates
Raymond Testa et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2015)
Executive Summary: Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
Dennis L. Stevens et al.
CLINICAL INFECTIOUS DISEASES (2014)
Pneumonia Due to Pseudomonas aeruginosa Part I: Epidemiology, Clinical Diagnosis, and Source
Shigeki Fujitani et al.
CHEST (2011)
Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America
Thomas M. Hooton et al.
CLINICAL INFECTIOUS DISEASES (2010)
Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America
Joseph S. Solomkin et al.
CLINICAL INFECTIOUS DISEASES (2010)
Share Paper
